Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, Nambu MD, Los G, Bender SL, Mroczkowski B, Christensen JG.

Cancer Res. 2007 May 1;67(9):4408-17.

2.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
3.

Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.

Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ.

Acta Pharmacol Sin. 2010 Sep;31(9):1181-8. doi: 10.1038/aps.2010.106. Epub 2010 Aug 9. Review.

4.

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.

Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ.

Expert Opin Investig Drugs. 2007 Feb;16(2):239-49. Review.

PMID:
17243944
5.

From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.

Dussault I, Bellon SF.

Anticancer Agents Med Chem. 2009 Feb;9(2):221-9. Review.

PMID:
19199866
6.

Apatinib for the treatment of gastric cancer.

Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, Zanotti L, Polom K, Reynolds AR, Fox SB, Generali D.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):887-92. doi: 10.1080/17474124.2016.1209407. Epub 2016 Jul 15. Review.

PMID:
27376400
7.

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics.

Chen MH, Kerkelä R, Force T.

Circulation. 2008 Jul 1;118(1):84-95. doi: 10.1161/CIRCULATIONAHA.108.776831. Review. No abstract available.

Supplemental Content

Support Center